North America Dengue Treatment Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2021 –2028 |
 Размер рынка (базовый год) |
USD 71.42 Million |
 Размер рынка (прогнозируемый год) |
USD 387.13 Million |
 CAGR |
% |
| Основные игроки рынка |
>Рынок лечения лихорадки денге в Северной Америке по штаммам (DENV-1, DENV-2, DENV-3, DENV-4, другие), пути передачи (передача от комара человеку и от матери ребенку), тип (лекарства, поддерживающая терапия, вакцинация и другие), тяжесть (неосложненная и тяжелая), путь введения (перорально и парентерально), способ приобретения (по рецепту и без рецепта (OTC)), конечный пользователь (больницы, специализированные клиники, домашняя медицинская помощь и другие), канал распространения (больничные аптеки, розничные аптеки, интернет-аптеки и другие), страна (США, Канада и Мексика) Тенденции отрасли и прогноз до 2028 года
Анализ рынка и идеи: рынок лечения лихорадки денге в Северной Америке
Ожидается, что рынок лечения лихорадки денге будет расти в прогнозируемый период с 2021 по 2028 год. Data Bridge Market Research анализирует, что рынок растет со среднегодовым темпом роста 23,9% в прогнозируемый период с 2021 по 2028 год и, как ожидается, достигнет 387,13 млн долларов США к 2028 году с 71,42 млн долларов США. Стратегические инициативы участников рынка и появление программ массовой вакцинации для лечения лихорадки денге, вероятно, станут ключевыми драйверами рынка лечения лихорадки денге.
Денге — вирусное заболевание, переносимое комарами, которое в последние годы быстро распространилось во всех регионах ВОЗ (Всемирной организации здравоохранения). Вирус денге в основном переносится самками комаров рода Aedes Aegyptus и в меньшей степени Ae. albopictus. Болезни, передаваемые этими переносчиками, — вирусы чикунгунья, желтая лихорадка и Зика. Денге распространена в тропиках и вызывается осадками, температурой , относительной влажностью и незапланированной быстрой урбанизацией с локальной изменчивостью риска.
Несмотря на контролируемые шаги, глобальный рост заболеваемости лихорадкой денге, наряду с возросшей частотой локализованных вспышек и потенциалом процветания видов Aedes, приводит к увеличению потребления варианта лечения лихорадки денге и, как ожидается, станет движущей силой для рынка лечения лихорадки денге. Стоимость лечения лихорадки денге выше, как указано в вышеприведенном заявлении, и с большим количеством осложнений, связанных с лихорадкой денге, таких как полиорганная недостаточность и другие, может увеличить общую стоимость терапии, что приводит к тому, что инфицированный человек избегает надлежащей терапии для лечения лихорадки денге, таким образом, может выступать в качестве сдерживающего фактора для рынка лечения лихорадки денге. Денге можно диагностировать традиционно с помощью серологического тестирования, но теперь, с модернизацией технологий, существуют различные текущие и разработанные способы обнаружения вируса, которые создадут возможности для рынка лечения лихорадки денге. Денге является трансмиссивным заболеванием с неспецифическими препаратами, такими как жаропонижающие и некоторые антибиотики, но профилактические меры и инициативы, предпринимаемые различными государственными учреждениями по всему миру, как ожидается, станут проблемой для рынка лечения лихорадки денге.
Отчет о рынке лечения лихорадки денге содержит подробную информацию о доле рынка, новых разработках и влиянии отечественных и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического обзора, наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.
Масштаб и размер рынка лечения лихорадки денге в Северной Америке
Рынок лечения лихорадки денге сегментирован на основе штаммов, передачи, типа, тяжести, пути введения, способа покупки, конечного пользователя и канала сбыта. Рост среди сегментов помогает вам анализировать нишевые карманы роста и стратегии для выхода на рынок и определять ваши основные области применения и разницу в ваших целевых рынках.
- На основе штаммов рынок лечения лихорадки денге сегментирован на DENV-1, DENV-2, DENV-3, DENV-4 и другие. В 2021 году сегмент DENV-2 доминирует на рынке, поскольку этот штамм имеет высокую распространенность, что приводит к более высоким случаям заражения лихорадкой денге. Хотя денге может быть вызвано и другими штаммами, наиболее доминирующее высокое клиническое осложнение наблюдается при DENV-2.
- На основе передачи рынок лечения лихорадки денге сегментируется на передачу от комара к человеку и передачу от матери к ребенку. В 2021 году сегмент передачи от комара к человеку доминирует на рынке, поскольку комары являются основным вектором передачи денге для различных штаммов вируса. Когда комар кусает инфицированного человека, он также заражается и получает вирус в кровь, а когда он снова кусает другого человека, вирус передается этому человеку. Вот почему передача от комара к человеку доминирует на рынке.
- По типу рынок лечения лихорадки денге сегментируется на лекарственные препараты , поддерживающую терапию , вакцинацию и др. В 2021 году сегмент лекарственных препаратов доминирует на рынке, поскольку различные препараты, используемые для лечения лихорадки денге, используются для управления лихорадкой денге уже очень давно.
- По степени тяжести рынок лечения лихорадки денге сегментируется на неосложненный и тяжелый. В 2021 году на рынке доминирует неосложненный сегмент, коэффициент перехода неосложненной лихорадки денге в тяжелую составляет менее 5%, что является наиболее важной причиной того, что неосложненный сегмент доминирует на рынке лечения лихорадки денге.
- На основе пути введения рынок лечения лихорадки денге сегментируется на пероральный и парентеральный . В 2021 году пероральный сегмент доминирует на рынке, поскольку большинство препаратов, которые принимаются для лечения симптомов лихорадки денге, принимаются перорально для снятия боли и лихорадки.
- On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
- On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
- On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.
Dengue Treatment Market Country Level Analysis
The dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.
The countries covered in the dengue treatment market report are the U.S., Canada and Mexico.
The U.S. is expected to dominate in the North America dengue treatment market due to growing focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Necessity of Dengue Treatment in Urban Areas and the Strategic Intiatives by Market Players are is Creating New Opportunities for Players in the Dengue Treatment Market
The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2010 to 2019.
Анализ конкурентной среды и доли рынка лечения лихорадки денге
Конкурентная среда рынка лечения лихорадки денге содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, широта и диапазон продукта, доминирование приложений, кривая жизненной линии технологий. Приведенные выше данные относятся только к фокусу компании на рынке лечения лихорадки денге.
Основными компаниями, предоставляющими лечение лихорадки денге, являются Aurobindo Pharma, Perrigo Company plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Fresenius Kabi USA (дочерняя компания Fresenius SE & Co. KGaA), Baxter, Vitric Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc. (дочерняя компания Teva Pharmaceutical Industries Ltd.), GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Sanofi и EMERGEX VACCINES и другие. Аналитики DBMR понимают конкурентные преимущества и проводят конкурентный анализ для каждого конкурента отдельно.
Сотрудничество, совместные предприятия и другие стратегии участников рынка расширяют возможности компании на рынке лечения лихорадки денге, что также дает организациям возможность улучшить свое предложение на рынке лечения лихорадки денге.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA DENGUE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 STRAINS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 PIPELINE ANALYSIS
6 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS
6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.
7.1 SYNTHETIC DRUGS
7.2 BIOMARKER
7.3 DIRECT ACTING ANTIVIRAL DRUGS
8 EPIDEMIOLOGY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING INCIDENCE IN DENGUE CASES
9.1.2 ADVENT OF VACCINATION PROGRAMS
9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING
9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE
9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
9.2 RESTRAINTS
9.2.1 HIGH COST OF TREATMENT
9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE
9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE
9.3 OPPORTUNITIES
9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION
9.3.4 INCREASE IN NORTH AMERICA TRAVEL AND RELATION WITH DENGUE
9.4 CHALLENGES
9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD
9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE
9.4.3 ALTERNATIVES FOR DENGUE TREATMENT
10 IMPACT OF COVID-19 ON NORTH AMERICA DENGUE TREATMENT MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISION BY MANUFACTURERS
10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
10.6 CONCLUSION
11 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS
11.1 OVERVIEW
11.2 DENV-3
11.3 DENV-2
11.4 DENV-1
11.5 DENV-4
11.6 OTHERS
12 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION
12.1 OVERVIEW
12.2 MOSQUITO-TO-HUMAN TRANSMISSION
12.3 MOTHER-TO-CHILD- TRANSMISSION
12.4 OTHERS
13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE
13.1 OVERVIEW
13.2 MEDICATION
13.2.1 ACETAMINOPHEN
13.2.2 ANTIBIOTICS
13.2.2.1 Ciprofloxacin
13.2.2.2 Chloramphenicol
13.2.2.3 Ceftriaxone
13.2.2.4 Ofloxacin
13.2.2.5 Others
13.2.3 IMMUNOGLOBULINS
13.2.4 CORTICOSTEROIDS
13.2.5 ANTI-VIRALS
13.2.6 OTHERS
13.3 SUPPORTIVE CARE
13.4 VACCINATION
13.4.1 DENGVAXIA (CYD-TDV)
13.4.2 DENVAX (TAK-003)
13.4.3 TETRAVAX-DV
13.4.4 TDEN PIV
13.5 OTHERS
14 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY
14.1 OVERVIEW
14.2 UNCOMPLICATED
14.3 SEVERE
15 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULES
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUBCUTANEOUS
15.3.3 OTHERS
16 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 PRESCRIPTION
16.3 OVER THE COUNTER (OTC)
17 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER
17.1 OVERVIEW
17.2 HOME HEALTHCARE
17.3 HOSPITALS
17.4 SPECIALTY CLINICS
17.5 OTHERS
18 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 RETAIL PHARMACIES
18.3 HOSPITAL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 NORTH AMERICA DENGUE TREATMENT MARKET, BY GEOGRAPHY
19.1 NORTH AMERICA
19.1.1 MEXICO
19.1.2 U.S.
19.1.3 CANADA
20 NORTH AMERICA DENGUE TREATMENT MARKET, COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 VIATRIS INC.
22.1.1 COMPANY SNAPSHOT
22.1.2 COMPANY SHARE ANALYSIS
22.1.3 PRODUCT PORTFOLIO
22.1.4 RECENT DEVELOPMENT
22.2 PFIZER INC.
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENT
22.4 PERRIGO COMPANY PLC
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 GLAXOSMITHKLINE PLC
22.5.1 COMPANY SNAPSHOT
22.5.2 REVENUE ANALYSIS
22.5.3 COMPANY SHARE ANALYSIS
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENT
22.6 DR. REDDY’S LABORATORIES LTD.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENT
22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENTS
22.9 ABIVAX
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 AUROBINDO PHARMA
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 BAXTER
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENT
22.12 EMERGEX VACCINES
22.12.1 COMPANY SNAPSHOT
22.12.2 PRODUCT PORTFOLIO
22.12.3 RECENT DEVELOPMENTS
22.13 HIKMA PHARMACEUTICALS PLC
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENT
22.14 SANOFI
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
Список таблиц
LIST OF TABLES
TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Список рисунков
LIST OF TABLES
TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION
TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION
TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION
TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION
TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)
TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)
TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)
TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET
FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
LIST OF FIGURES
FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID
FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET
FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020
FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)
FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)
FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020
FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)
FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)
FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020
FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).
FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020
FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)
FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
